- Home
- BTAI vs ACCS Comparison
BTAI vs ACCS Comparison
Compare BTAI & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- ACCS
- Stock Information
- Founded
- BTAI 2017
- ACCS 1988
- Country
- BTAI United States
- ACCS United States
- Employees
- BTAI N/A
- ACCS N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- ACCS Publishing
- Sector
- BTAI Health Care
- ACCS Consumer Discretionary
- Exchange
- BTAI Nasdaq
- ACCS Nasdaq
- Market Cap
- BTAI 52.7M
- ACCS 46.2M
- IPO Year
- BTAI 2018
- ACCS N/A
- Fundamental
- Price
- BTAI $3.79
- ACCS $10.80
- Analyst Decision
- BTAI Strong Buy
- ACCS Strong Buy
- Analyst Count
- BTAI 4
- ACCS 1
- Target Price
- BTAI $40.00
- ACCS $14.00
- AVG Volume (30 Days)
- BTAI 14.1M
- ACCS 10.9K
- Earning Date
- BTAI 08-12-2025
- ACCS 11-06-2025
- Dividend Yield
- BTAI N/A
- ACCS N/A
- EPS Growth
- BTAI N/A
- ACCS N/A
- EPS
- BTAI N/A
- ACCS N/A
- Revenue
- BTAI $868,000.00
- ACCS $22,562,000.00
- Revenue This Year
- BTAI N/A
- ACCS $0.03
- Revenue Next Year
- BTAI $597.46
- ACCS $11.45
- P/E Ratio
- BTAI N/A
- ACCS N/A
- Revenue Growth
- BTAI N/A
- ACCS 26.44
- 52 Week Low
- BTAI $1.17
- ACCS $7.79
- 52 Week High
- BTAI $13.36
- ACCS $13.35
- Technical
- Relative Strength Index (RSI)
- BTAI 48.02
- ACCS 43.67
- Support Level
- BTAI $3.41
- ACCS $10.30
- Resistance Level
- BTAI $4.20
- ACCS $11.15
- Average True Range (ATR)
- BTAI 0.62
- ACCS 0.41
- MACD
- BTAI -0.27
- ACCS -0.01
- Stochastic Oscillator
- BTAI 11.05
- ACCS 35.71
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.